Gosset in China
China’s biopharma, tracked daily
China now starts a large share of the world’s new drugs and clinical trials, and more and more of the licensing deals that take them abroad. Gosset reads Chinese trials, regulators, patents, company filings and news every day and links them into the same graph as the rest of the world, so you see a Chinese program move when it moves.
Updated
China’s share of global drug development
- of drug trials worldwide have a site in China
- 25%
- of the world’s drugs are developed in China
- 16%
- Chinese records read, about 710 new a day
- 964.9K
China to the world
From Chinese labs to partners worldwide
A growing share of the drugs Western companies license begin in China. Gosset links each Chinese drug to the trials that test it, the company that develops it and every deal that moves its rights abroad, so you can follow a program from its first Chinese trial to its global partner.
- Out-licensing deals, China to partners abroad
- 1,448
- Drugs developed in China
- 25,669
- Drug trials with a site in China
- 115,189
- Companies based in China
- 20,747
- Deals with a Chinese party
- 13,398
What we read in China
10 Chinese sources, grouped by type. We never list them by name, only what they give you and how fresh it is.
Clinical trials
Trials registered in China and global trials with sites in mainland China, linked to the drugs, targets and diseases they study.
218,191 records
about 84 added per dayWithin a day
newestUp to date
Regulator
Drug approvals from China's national drug regulator, so you see what is on the market in China.
160,518 records
about 4 per day on average, added in weekly batchesWithin a week
newestUpdated weekly
Patents
Chinese patent filings and grants linked to the drugs and targets they cover, plus new Chinese applications as they publish.
541,365 records
about 291 added per dayWithin a week
newestUp to date
Company materials
What Chinese biopharma companies publish themselves: stock-exchange announcements and posts from their official accounts.
9,500 records
about 317 added per dayWithin a day
newestUp to date
News
Biopharma news and press releases about companies based in mainland China, tied to the drugs and companies they mention.
35,318 records
about 14 added per dayWithin a day
newestUp to date
Every Chinese drug and trial is mapped to the same target, modality and disease ontologies as the rest of Gosset, so one question finds Chinese and Western programs together. See how Gosset works
China questions, answered with sources
- Which China-origin ADCs now in Phase 2 or 3 have licensing agreements with US partners since 2023?
- Find the phase 1 trials studying drugs that target B7-H3
- What’s the competitive landscape of Claudin 18.2?
CSPC Megalith licensed its Nectin-4 ADC CRB-701 (SYS6002) to Corbus Pharmaceuticals in February 20231; in China it is now in Phase 3 for cervical cancer2. On 3 August 2026 Jiangsu Alphamab licensed JSKN016, a TROP2 × HER3 bispecific ADC in Phase 3 for triple-negative breast cancer, to Pathos AI for every territory outside mainland China, Hong Kong, Macau and Taiwan3.
Ask Gosset about China
China means mainland China: Hong Kong, Macau and Taiwan are not counted in any China figure. Drugs are counted once each, by their developer’s country; trials are drug intervention trials with at least one site in mainland China; companies are those located there; a deal counts when any buyer or seller is in mainland China, and out-licensing when a Chinese party licenses or sells rights to a party outside it. Shares compare with all trials and drugs Gosset serves worldwide. Per-day figures average the last 30 days; hover a time for the exact UTC timestamp.